Retrophin

San Diego, United States Founded: 2011 • Age: 15 yrs Listed
Drugs are developed for debilitating and life-threatening diseases.

About Retrophin

Retrophin is a publicly listed company based in San Diego (United States) founded in 2011. Drugs are developed for debilitating and life-threatening diseases. Retrophin has raised $29 million across 2 funding rounds from investors including MSMBAinUSA. The company has 380 employees. Retrophin has completed 2 acquisitions, including Manchester Pharma and Orphan Technologies. Its chief executive, as recorded, is Eric Dube. Its focus areas include Diversified Pharmaceuticals. Its legal entity is RETROPHIN, INC.

Company details

Founded in 2011 and based in San Diego, United States, Retrophin operates in the biopharmaceutical sector. Focus is placed on the discovery, acquisition, development, and commercialization of therapies targeting diseases with limited treatment options. Three drugs are currently marketed for homozygous cystinuria, bile acid synthesis disorders, and gallstones. Additional candidates are in development for focal segmental glomerulosclerosis and pantothenate kinase-associated neurodegeneration. Leadership is provided by CEO Eric Dube.

  • Headquarters San Diego, United States
  • Employees 380
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website retrophin.com
  • Social LinkedIn X Facebook
  • Legal Name Retrophin, Inc.
Key Metrics
  • Total Equity Funding
    $29M (USD)

    in 2 rounds

  • Latest Funding Round
    $25M (USD), Series B

    Oct 2013

  • Investors
  • Employee Count
    380
  • Investments & Acquisitions

Funding Insights of Retrophin

Retrophin has successfully raised a total of $29M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $25 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $29M
  • Total Rounds 2
  • Last Round Series B β€” $25M
  • First Round $4M

    (May 2012)

  • Investors Count 1

All 2 funding rounds of Retrophin with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2013$25MSeries B––
–
May 2012$4MSeries A––
Valuation history

1 investors in total: 1 institutional.

Investors in Retrophin

Retrophin has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include MSMBAinUSA.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Provides online guidance for students seeking to study abroad.
2013msmbainusa.comMumbai, India
Premium access

Investor details for Retrophin

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Retrophin

5 people are tracked at Retrophin (4 in leadership, 1 in team); the tracked headcount is 380.

NameRoleGroup
Eric Dube
CEOLeadership
Noah L. Rosenberg
Chief Medical OfficerLeadership
Laura M. Clague
Chief Financial OfficerLeadership
Peter Heerma
Chief Commercial OfficerLeadership
Elizabeth Reed
General Counsel and Corporate SecretaryTeam
Premium access

Complete people profiles for Retrophin

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Retrophin

Retrophin has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Manchester Pharma and Orphan Technologies.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Enzyme replacement therapy for homocystinuria is being developed.
orphantechnologies.comLexington, United States2010Oct 2020$90M
Therapeutic modalities for ultra-rare diseases are developed and commercialized.
manchesterpharma.comFort Collins, United States2008Feb 2014$62.5M
Premium access

Complete acquisition details for Retrophin

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Retrophin

6 dated milestones of Retrophin across 9 years, from founding to its latest funding, stage changes and deals.

  1. Founded Retrophin is founded.
  2. Funding First funding round of $4.0M.
  3. Funding Latest funding round, Series B, of $25.0M.
  4. IPO Lists on the stock exchange (IPO).
  5. Acquisition Acquires Manchester Pharma.
  6. Acquisition Acquires Orphan Technologies.

Web traffic of Retrophin

Websites that share an audience with Retrophin (retrophin.com).

Similar websites

Websites whose visitors overlap most with Retrophin. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
missionpharmacal.com
100%
2.8K#8,693,471View details
arraybiopharma.com
98%
View details
dddmag.com
dddmag.com
85%
–
ppdi.com
ppdi.com
85%
#404,899–
takeda.com
85%
620.1K#93,966View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 14 similar websites and full traffic analytics for Retrophin

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 14 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Pharmaceuticals & Distribution

3 companies that operate in the same segment as Retrophin (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
2014New York, New York, United StatesUSD 1.3 BUSD 8.26 M750
Developer of pharmaceutical products for treating multiple diseases
1980Thousand Oaks, California, United StatesUSD 33.23 B28,000
Biopharmaceutical research and drug development are conducted globally by AbbVie.
2012Chicago, Illinois, United StatesUSD 5.33 B55,000
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Retrophin

Premium access

Complete news archive for Retrophin

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Retrophin

Retrophin was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Retrophin is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Eric Dube is the CEO of Retrophin, as recorded in our data.

Retrophin is a funded company, having raised a total of $29M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on May 2012.

Retrophin has 380 employees.

Founded in 2011 and based in San Diego, United States, Retrophin operates in the biopharmaceutical sector. Focus is placed on the discovery, acquisition, development, and commercialization of therapies targeting diseases with limited treatment options. Three drugs are currently marketed for homozygous cystinuria, bile acid synthesis disorders, and gallstones. Additional candidates are in development for focal segmental glomerulosclerosis and pantothenate kinase-associated neurodegeneration. Leadership is provided by CEO Eric Dube.

Retrophin has made 2 acquisitions, including Manchester Pharma, and Orphan Technologies.

Retrophin has 1 investor. Key investors include MSMBAinUSA.

Retrophin operates through Retrophin, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available